Edition:
United States

Intercept Pharmaceuticals Inc (ICPT.OQ)

ICPT.OQ on NASDAQ Stock Exchange Global Select Market

62.24USD
3:59pm EST
Change (% chg)

$0.44 (+0.71%)
Prev Close
$61.80
Open
$61.76
Day's High
$63.38
Day's Low
$61.16
Volume
161,256
Avg. Vol
388,023
52-wk High
$135.59
52-wk Low
$54.98

Select another date:

Wed, Nov 1 2017

BRIEF-Intercept Pharma reports qtrly ‍revenue $41.3 mln vs $5.2 million​

* Intercept Pharmaceuticals reports third quarter 2017 financial results and provides business update

BRIEF-Intercept Pharma posts positive results from Phase 2 AESOP trial

* Intercept announces positive results from Phase 2 AESOP trial evaluating OCA for the treatment of patients with primary sclerosing cholangitis at The Liver Meeting 2017

Intercept does not expect restrictive boxed warning for liver drug

Intercept Pharmaceuticals Inc said on Monday its liver drug, Ocaliva, could carry a boxed warning to help ensure proper dosing but the drugmaker also said it does not expect the updated labeling to be restrictive, sending its shares higher.

UPDATE 2-Intercept does not expect restrictive boxed warning for liver drug

Sept 25 Intercept Pharmaceuticals Inc said on Monday its liver drug, Ocaliva, could carry a boxed warning to help ensure proper dosing but the drugmaker also said it does not expect the updated labeling to be restrictive, sending its shares higher.

Intercept Pharma says possible Ocaliva boxed warning will not be restrictive

Sept 25 Intercept Pharmaceuticals Inc said on Monday an update to the label of its liver drug, Ocaliva, could include a boxed warning to help ensure proper dosing of patients, but added that it did not expect the change to be restrictive.

BRIEF-Intercept Pharmaceuticals comments on Ocaliva safety and dosing in liver disease patients​

* Intercept Pharmaceuticals Inc comments on Ocaliva (obeticholic acid) safety and dosing in primary biliary cholangitis (PBC) patients​

FDA warns of death, liver injury risks from Intercept's drug

The U.S. Food and Drug Administration (FDA) warned on Thursday that Intercept Pharmaceuticals Inc's drug Ocaliva was being incorrectly dosed in some patients with a rare liver disease, increasing the risk of liver injury and death.

FDA warns of death, liver injury risks from Intercept's drug

The U.S. Food and Drug Administration (FDA) warned on Thursday that Intercept Pharmaceuticals Inc's drug Ocaliva was being incorrectly dosed in some patients with a rare liver disease, increasing the risk of liver injury and death.

UPDATE 1-FDA warns of death, liver injury risks from Intercept's drug

Sept 21 The U.S. Food and Drug Administration (FDA) warned on Thursday that Intercept Pharmaceuticals Inc's drug Ocaliva was being incorrectly dosed in some patients with a rare liver disease, increasing the risk of liver injury and death.

FDA warns of liver injury, death risks from Intercept's drug

Sept 21 The U.S. Food and Drug Administration (FDA) warned on Thursday that Intercept Pharmaceuticals Inc's drug Ocaliva was being incorrectly dosed in some patients with a rare liver disease, increasing the risk of liver injury and death.

Select another date: